Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Debuts Rapidly Manufactured Autologous CAR-Ts

Executive Summary

The company presented early data on two candidates at the ASH meeting that use a less than two-day manufacturing process, YTB323 in diffuse large B-cell lymphoma and PHE885 in multiple myeloma.

You may also be interested in...



Novartis’s John Tsai On The Four Philosophies Driving R&D

Scrip spoke with global development head and chief medical officer John Tsai about the factors Novartis considers when it decides which R&D programs to advance, including externally sourced assets. 

ASH Preview: Three Areas To Watch In Hematology-Oncology

Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.

Novartis's Kymriah Comes Up Short In NHL Study

The BELINDA study investigating Kymriah as second-line treatment in aggressive B-cell non-Hodgkin lymphoma has missed its primary endpoint, thwarting Novartis's hopes of getting the CAR-T therapy into earlier-stage use.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel